CytoDyn Insider Urbach Files Form 4 on Ownership Changes

TL;DR

**CytoDyn insider Urbach filed a Form 4, signaling potential ownership changes.**

AI Summary

This Form 4 filing indicates that Tanya Durkee Urbach, a reporting person for CytoDyn Inc., filed a statement of changes in beneficial ownership of securities on March 24, 2026, for a period ending March 20, 2026. While the filing itself doesn't detail specific transactions, it signals that an insider's ownership stake may have changed. This matters to investors because insider transactions can sometimes provide clues about a company's future prospects, as insiders typically have more information than the general public.

Why It Matters

Insider transaction filings like this can signal changes in confidence or strategy by key personnel, which can influence investor perception and stock performance.

Risk Assessment

Risk Level: low — This filing is purely administrative and does not disclose specific transactions or financial risks, only that a change in ownership occurred or will be reported.

Analyst Insight

An investor should monitor subsequent Form 4 filings from Tanya Durkee Urbach to see if specific transactions (buys or sells) are reported, as these would provide more actionable insights into insider sentiment regarding CytoDyn Inc.

Key Players & Entities

• Urbach Tanya Durkee (person) — Reporting Person
• CytoDyn Inc. (company) — Issuer
• 0001897672 (person) — CIK of Reporting Person
• 0001175680 (company) — CIK of Issuer

FAQ

Filing Documents

• tm269618-8_4seq1.html (4)
• tm269618-8_4seq1.xml (4) — 5KB
• 0001104659-26-033963.txt ( ) — 6KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Urbach Tanya Durkee (Last) (First) (Middle) 1111 MAIN STREET, SUITE 660 (Street) VANCOUVER WASHINGTON 98660 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [ CYDY ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Non-qualified stock option (right to buy) $ 0.28 03/20/2026 A 574,385 (1) (2) 03/20/2036 Common Stock 574,385 $ 0 574,385 D Explanation of Responses: 1. This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan"). 2. The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027. /s/ Tyler Blok, Attorney-in-Fact for Tanya Durkee Urbach 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR